IPI-926
PreclinicalSmall molecule
IPI-926 is one of 45 small molecule programs targeting Treatment. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Theo-Dur
PfizerPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Solid Tumor Malignancies1 trial
Chondrosarcoma1 trial
Pancreatic Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IPI-926. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IInfinity Pharmaceuticals, Inc.